Catalent (NYSE:CTLT) Reaches New 1-Year High – Time to Buy?

Shares of Catalent, Inc. (NYSE:CTLT) hit a new 52-week high during trading on Monday . The company traded as high as $62.28 and last traded at $62.25, with a volume of 899537 shares traded. The stock had previously closed at $61.83.

Analyst Ratings Changes

CTLT has been the subject of several analyst reports. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $63.40.

Catalent Price Performance

The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a market cap of $11.48 billion, a P/E ratio of -27.55, a PEG ratio of 2.46 and a beta of 1.15. The company has a fifty day moving average price of $60.15 and a two-hundred day moving average price of $58.85.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the firm earned ($0.10) EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Equities analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp increased its holdings in shares of Catalent by 1.5% during the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after acquiring an additional 113,095 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after acquiring an additional 2,299,784 shares during the last quarter. Alpine Associates Management Inc. increased its holdings in shares of Catalent by 3.4% during the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock worth $129,082,000 after acquiring an additional 69,875 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Catalent by 14.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock worth $108,559,000 after acquiring an additional 250,999 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Catalent by 181.5% during the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after acquiring an additional 1,169,044 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.